Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2024
0mins
Source: Benzinga
Needham upgraded Haemonetics to Buy from Hold with a $112 price target, citing improved margin outlook.
Key factors for margin growth: reduced low-margin Plasma sales and expanded high-margin Interventional Technologies sales.
Analyst Views on NBSM
Wall Street analysts forecast NBSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBSM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 27.020
Low
Averages
High
Current: 27.020
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
